Bostjan Seruga, Ian F Tannock. Show Affiliations »
Abstract
Entities: Chemical
Mesh: See more » Antineoplastic Agents/administration & dosageBreast Neoplasms/drug therapyBreast Neoplasms/enzymologyBreast Neoplasms/geneticsClinical Trials, Phase II as TopicDrug Administration ScheduleFemaleHumansLapatinibProtein Kinase Inhibitors/administration & dosageProtein Kinase Inhibitors/adverse effectsQuinazolines/administration & dosageQuinazolines/adverse effectsRandomized Controlled Trials as TopicReceptor, ErbB-2/biosynthesisReceptor, ErbB-2/genetics
Substances: See more » Antineoplastic AgentsProtein Kinase InhibitorsQuinazolinesLapatinibReceptor, ErbB-2
Year: 2008 PMID: 18458041 DOI: 10.1200/JCO.2008.16.5282
Source DB: PubMed Journal: J Clin Oncol ISSN: 0732-183X Impact factor: 44.544